Solvay and Berna Biotech sign a license agreement for vaccine against Pseudomonas aeruginosa in Cystic Fibrosis patients
04-Aug-2005
Solvay Pharmaceuticals acquires the exclusive distribution rights for the USA, Canada, Latin America and some other countries.
The vaccine Aerugen® will be developed by Berna Biotech. The product has obtained Orphan Drug designation in USA. Berna will submit the FDA file and the launch in the USA is expected to take place by 2009. More countries will follow subsequently.
Most read news
Organizations
Berna Biotech
Solvay
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.